Resumo
Objetivo: Analisar o papel dos monócitos e macrófagos na modulação da resposta imune e na determinação dos diferentes desfechos clínicos da Doença de Chagas (DC). Revisão bibliográfica: Monócitos e macrófagos são centrais na resposta imune ao T. cruzi, atuando tanto no controle inicial da parasitemia quanto na modulação da imunidade adaptativa. Alterações nas subpopulações monocitárias e na expressão de moléculas coestimulatórias podem estar relacionadas à evolução para formas sintomáticas. Nos tecidos, a plasticidade dos macrófagos, influenciada por citocinas, metabolismo, vias de sinalização e pelo microambiente, determina o equilíbrio entre perfis pró-inflamatórios e regulatórios. A predominância de estados M2-like e o remodelamento cardíaco favorecem a persistência do parasita e a inflamação crônica de baixa intensidade que caracteriza os quadros clínicos mais graves. Considerações finais: Monócitos e macrófagos moldam a evolução clínica da DC por meio de sua plasticidade funcional e de interações complexas com mecanismos imunológicos, metabólicos e teciduais. Embora não atuem isoladamente, sua contribuição é decisiva para o equilíbrio entre controle parasitário, inflamação crônica e desenvolvimento de cardiopatia. A compreensão integrada desses processos destaca esses fagócitos como potenciais biomarcadores e alvos para intervenções imunomodulatórias que considerem simultaneamente fatores parasitários, adaptativos e microambientais.
Referências
ANSA-ADDO EA, et al. Monocyte-derived extracellular vesicles, stimulated by Trypanosoma cruzi, enhance cellular invasion in vitro via activated TGF-β1. Journal of Extracellular Vesicles, 2024; e70014.
BEARD CB, et al. Chagas disease in a domestic transmission cycle in southern Texas, USA. Emerging Infectious Diseases, 2003; 9(1): 103-110.
CARVALHO AMRS, et al. Chagas cardiomyopathy is associated with high susceptibility to T. cruzi infection in monocyte-derived macrophages and predominance of CD4+CD45RO+ T-cells. Acta Tropica, 2023; 237: 106749.
CERBÁN FM, et al. Signaling pathways that regulate Trypanosoma cruzi infection and immune response. BBA Molecular Basis of Disease, 2020; 1866(1): 165707.
DIAS JCP, et al. II Consenso Brasileiro em doença de Chagas, 2015. Epidemiologia e Serviços de Saúde, 2016; 25: 7-86.
GOMES JAS, et al. Impaired phagocytic capacity and modulatory cytokine profile in neutrophils and monocytes from indeterminate Chagas disease. Immunobiology, 2012; 217(10): 1005-1016.
GOMES JAS, et al. Inflammatory mediators down-regulate proliferation and increase cytokines in polar forms of Chagas disease. Human Immunology, 2014; 75(1): 20-28.
GÓMEZ-OLARTE S, et al. Intermediate monocytes and cytokine production associated with severe forms of chagas disease. Frontiers in immunology. 2019; 19(10):1671.
HOLZMULLER P, et al. Trypanosomatid factors modulate L-arginine inducible metabolism in macrophages. Frontiers in Immunology, 2018; 9:778.
KOO S, et al. Macrophages promote oxidative metabolism to drive nitric oxide generation in response to Trypanosoma cruzi. Infection and Immunity, 2016; 84(6): e00014.
LOGULLO J, et al. Increased Trypanosoma cruzi growth in macrophages cultured on collagen I. Life, 2023; 13(4): 1063.
MACALUSO G, et al. A review on the immunological response against Trypanosoma cruzi. Pathogens, 2023; 12(3): 486.
PIERALISI AV, et al. Fenofibrate increases non-classical monocytes and modulates cytokines in asymptomatic Chagas disease. Frontiers in Cellular and Infection Microbiology, 2022; 11: 785166.
PINTO BF, et al. CD86 expression by monocytes influences an immunomodulatory profile in asymptomatic chronic Chagas disease. Frontiers in Immunology, 2018; 9: 454.
PONCINI CV, GONZÁLEZ-CAPPA SM. Dual role of monocyte-derived dendritic cells in Trypanosoma cruzi infection. European Journal of Immunology, 2017; 47(11): 1936-1948.
REGO N, et al. Comparative microRNA profiling of Trypanosoma cruzi-infected human cells. Frontiers in Cellular and Infection Microbiology, 2023; 13: 1187375.
SOARES AKA, et al. Expression of co-stimulatory molecules CD80 and CD86 in CD14+HLA-DR+ monocytes after recombinant T. cruzi antigens. Revista da Sociedade Brasileira de Medicina Tropical, 2016; 49(5): 632-636.
SOUZA PEA, et al. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infection and immunity, 2004;72(9):5283-91.
SOUZA PEA, et al. Trypanosoma cruzi infection modulates costimulatory molecules and cytokines in monocytes and T cells. Infection and Immunity, 2007; 75(4): 1886-1894.
TANOWITZ HB, et al. Trypanosoma cruzi and Chagas disease: innate immunity, ROS, and cardiovascular system. InVascular responses to pathogens, 2016; 1:183-193.
TARLETON RL. Immune system recognition of Trypanosoma cruzi. Current Opinion in Immunology, 2007; 19(4): 430-434.
VELLOZO NS, et al. Immunopathogenesis in Trypanosoma cruzi infection: suppressed macrophages and apoptotic cells. Frontiers in Immunology, 2023; 14: 1244071.
VOLPINI X, et al. Trypanosoma cruzi exploits Wnt signaling to promote intracellular replication in macrophages. Frontiers in Immunology, 2018; 9: 859.
ZANLUQUI NG, et al. Macrophage polarization in Chagas disease. Journal of Clinical & Cellular Immunology, 2015; 6(6): 4172.
